However, recent advances in melanoma biology have led to newer therapies, such as immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) and targeted BRAF/MEK inhibitors, which have proven effective in prolonging recurrence-free survival and improving patient outcomes [15]. Here, MAP2K7 is linked to melanoma.